New HIV drug IAP086 gets first human safety test
NCT ID NCT07596888
First seen May 24, 2026 · Last updated May 24, 2026
Summary
This early-stage study tests the safety of a single dose of a new experimental drug, IAP086, in 30 people with HIV whose virus is already well-controlled by their regular antiretroviral therapy (ART). Participants will receive one infusion of IAP086 and be closely monitored for side effects over 28 days. The goal is to see if the drug is safe enough to study further, not to cure HIV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of North Carolina
Chapel Hill, North Carolina, 27514, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.